Because it remains unclear whether noninvasive ventilation (NIV) is an effective therapy for cardiogenic pulmonary edema secondary to acute myocardial infarction (AMI), we retrospectively evaluated our experience with NIV in the treatment of pulmonary edema secondary to AMI and other cardiac conditions.
cute cardiogenic pulmonary edema, a frequent cause of respiratory failure, remains a serious clinical problem. Noninvasive ventilation (NIV), using continuous positive airway pressure (CPAP) or bilevel positive airway pressure (Bilevel-PAP), reduces the need for mechanical ventilation with endotracheal intubation by improving gas exchange and hemodynamic parameters. 1-8 Meta-analyses have shown that NIV, especially CPAP, improves survival rate in cardiogenic pulmonary edema. 9- 14 Cardiogenic pulmonary edema can have various etiologies, 15 with acute myocardial infarction (AMI) being the most common. Masip et al reported that AMI was associated with a high rate of endotracheal intubation in patients with pulmonary edema treated with NIV. 16 Furthermore, AMI was an independent predictor of NIV failure resulting in a need for mechanical ventilation with endotracheal intubation. In the latest Canadian guidelines, NIV is not recommended in acute coronary syndrome requiring urgent coronary revascularization because most of the randomized control trials excluded patients who required acute coronary revascularization or who had acute coronary syndrome. 17 In contrast, previous studies have shown that NIV is a safe and effective method of improving gas exchange and hemodynamic parameters in cases of cardiogenic pulmonary edema, including pulmonary edema because of AMI. 1-3,5, 18 We previously reported that CPAP is a highly effective treatment for patients with severe cardiogenic pulmonary edema complicating AMI. 4 A recent meta-analysis showed that NIV reduced mortality rate in patients with acute cardiogenic pulmonary edema secondary to acute myocardial ischemia or infarction. 14 However, the number of patients studied to date is small, with the largest recent trial evaluating NIV in the treatment of cardiogenic pulmonary edema secondary to AMI involving only approximately 40 patients. 19 It remains unclear whether NIV is an effective therapy in patients with severe cardiogenic pulmonary edema secondary to AMI. There are currently no generally accepted criteria for the use of NIV in patients with pulmonary edema and AMI. The purpose of this study was to retrospectively evaluate and A 2587 NIV in AMI Patients With Pulmonary Edema compare our experience with NIV in patients with cardiogenic pulmonary edema secondary to AMI and other cardiac conditions.
Methods

Patients and Diagnostic Criteria
The data of 6,745 patients admitted to the Cardiac Care Unit (CCU) of Nippon Medical School Hospital with a diagnosis of acute cardiogenic pulmonary edema over an 8-year period (January 1, 2001 to December 31, 2008) were analyzed retrospectively. The hospital's ethics committee has established that a retrospective study involving research of medical records can be conducted without authorization from the committee.
Cardiogenic pulmonary edema was diagnosed if a patient had sudden onset of dyspnea, typical findings on chest radiography, and widespread rales without a history suggesting pulmonary aspiration or infection. AMI was defined according to the redefined European Society of Cardiology/American College of Cardiology (ESC/ACC) criteria. 20 We conducted a retrospective search of all eligible patients, including all patients admitted with acute cardiogenic pulmonary edema in whom NIV was used as initial ventilatory support in the CCU. The indication for NIV was determined by the physician in charge, and required acute cardiorespiratory distress defined by hypoxemia (PaO2/FiO2 <300 mmHg) and at least one of the following: use of accessory muscles, extensive diaphoresis, mottling, or marked intolerance to being supine. Patients with chronic obstructive pulmonary disease or bronchial asthma, surgery within the past month, cancer or hematological malignancy with a poor short-term prognosis, do-not-resuscitate or -intubate orders on admission, acute lung injury, coma, or shock were not included in the analysis. Cardiogenic shock was defined according to standard criteria. 21 Coma was defined by a Glasgow Coma Scale score <10 on admission. Patients were also excluded from the analysis if they were intubated with mechanical ventilation prior to NIV during the same CCU admission.
A total of 425 patients, including 261 patients with acute cardiogenic pulmonary edema, were treated with NIV during the study period. Among these, 206 patients met the inclusion criteria and were included in the analysis. Patients were divided into 2 groups according to the etiology of acute cardiogenic pulmonary edema: an AMI group and a non-AMI group.
Noninvasive Ventilation
In the CCU, NIV was performed according to standardized procedures. Patients received CPAP via a full-or total-face mask using a BiPAP Vision machine (Respironics, Murrysville, PA, USA) as first-line treatment. The initial positive end-expiratory pressure was 4-10 cmH2O, and was adjusted to improve patient comfort. FiO2 was adjusted to achieve SpO2 >95%. If the patient complained of dyspnea at 30 min after initiation of CPAP treatment, NIV was changed to Bilevel-PAP. Clinical response was monitored regularly (heart rate, blood pressure, level of consciousness, respiratory rate, and SpO2), together with patient discomfort, air leaks around the mask, gastric distension, pressure sores, and signs of facial skin necrosis. Arterial blood gases were regularly analyzed prior to initiation of NIV, and then every hour for 6 h. Arterial blood gases were also analyzed when the patient was successfully weaned from NIV, or intubated. Successful NIV was defined as rapid improvement in clinical status and gas exchange, with recovery of the patient's previous stable respiratory condition. Failure of NIV was defined as the need for endotracheal intubation and mechanical ventilation during the CCU stay, irrespective of reason. Endotracheal intubation was subdivided according in its timing: following NIV was defined as intubated directly from NIV, or after weaning from NIV, which was defined as intubated after successful weaning from NIV. Echocardiography was performed within 1 h of admission to CCU.
Data Collection
We retrospectively collected the following information for the time of admission: age, sex, primary diagnosis, history of prior MI, diabetes mellitus, hypertension, dyslipidemia, or chronic renal failure on hemodialysis, Glasgow Coma Scale score, Acute Physiology And Chronic Health Evaluation (APACHE) II score, and left ventricular ejection fraction. The following information was collected for the CCU stay: development of new MI, initial treatments (including inotropic agents, vasodilators, and diuretics), intra-aortic balloon pumping to assist circulation, and outcome, including tracheal intubation, CCU mortality, and in-hospital mortality. Arterial blood gases, vital signs, and respiratory rate were recorded prior to initiation of NIV, at 1, 2, and 6 h after initiation of NIV, and at weaning from NIV or tracheal intubation. CPAP and Bilevel-PAP pressures and FIO2 were also recorded, as well as the reason for tracheal intubation. Our treatment strategies for acute cardiogenic pulmonary edema were based on the guidelines for the management of patients with AMI 22 and acute heart failure.
23,24
Statistical Analysis A 2-way analysis of variance and Bonferroni multiple comparisons were used to compare differences within each group over time. The Mann-Whitney test was used to evaluate differences between groups in patients' characteristics at particular time points. Fisher's exact test or χ2 test was used to compare patients' baseline characteristics, endotracheal intubation rate, CCU mortality rate, and in-hospital mortality rate between groups. All statistics were calculated using Dr SPSS II (SPSS, Chicago, IL, USA). All values are reported as the mean ± standard deviation. P<0.05 was considered statistically significant.
Results
Patient Characteristics (Table 1) The study group consisted of 206 patients with acute cardiogenic pulmonary edema, divided into an AMI group (53 patients) and a non-AMI group (153 patients). The etiologies of pulmonary edema in the non-AMI group were prior MI (n=57), cardiomyopathy (n=33), valvular disease (n=31), hypertensive heart disease (n=25), and other (n=7). Patients in the AMI group were more likely to have dyslipidemia and less likely to have hypertension than those in the non-AMI group. Serum creatinine levels were high in both groups, indicating moderate renal insufficiency. Left ventricular ejection fraction was low (approximately 30%) in both groups. All patients in the AMI group had Killip class III heart failure.
Treatment During NIV (Table 2)
The mean duration of NIV was 33.3 h (range, 2-171 h) in the AMI group and 25.9 h (range, 2-181 h) in the non-AMI group. NIV tended to be more prolonged in the AMI group than in (Table 3 ) Baseline systolic and diastolic blood pressures were significantly lower in the AMI group than in the non-AMI group. Heart rate, blood pressure, and respiratory rate were all significantly lower in both groups at 1 h after initiation of NIV, and were maintained until weaning from NIV. However, heart rate was significantly higher in the AMI group than in the non-AMI group at both 6 h and at weaning from NIV, and the systolic blood pressure was significantly lower in the AMI group than in the non-AMI group throughout the period studied. The PaO2/FiO2 ratio, an indicator of oxygenation, was significantly higher at 1 h after initiation of NIV in both groups. Acidemia was observed in the non-AMI group at baseline, and pH was significantly higher at 1 h after initiation of NIV in both groups.
Patients' Outcomes (Table 4)
The weaning rate from NIV was similar in the AMI and non-AMI groups (48 patients, 90.6% vs. 139 patients, 90.8%; P=0.950). However, 4 patients in the AMI group who were weaned from NIV subsequently required intubation for the following reasons: cardiac rupture (86 h later), recurrent AMI (82 h later), refractory ventricular arrhythmia (37 h later), and pneumonia (32 h later). In the non-AMI group, 1 patient weaned from NIV subsequently required intubation because of stroke (174 h later). The percentage of patients who required endotracheal intubation while in the CCU was similar in the AMI and non-AMI groups (9 patients, 17.0% vs. 15 patients, 9.8%; P=0.160). In the non-AMI group, lower initial systolic blood pressure was related to a higher intubation rate (<100 mmHg, 25.0%; 100-140 mmHg, 17.0%; >140 mmHg, 8.0%) but this trend was not statistically significant (P=0.088). AMI occurred in 8 patients (5.2%) in the non-AMI group. The CCU mortality rate was higher in the AMI group than in the non-AMI group, but the difference was not statistically significant (9.4% vs. 2.6%, P=0.051). The in-hospital mortality rate was similar in the AMI and non-AMI groups (13.1% vs. 9.8%, P=0.489).
Discussion
This study demonstrates that NIV was effective in improving vital signs and oxygenation, and in avoiding endotracheal intubation, in patients with cardiogenic pulmonary edema of all etiologies, including AMI. The outcome for patients with AMI and treated with NIV depended primarily on the severity of the course of AMI and not on the severity of acute respiratory failure. To our knowledge, this is the largest study of the use of NIV in patients with pulmonary edema secondary to AMI. In patients with cardiogenic pulmonary edema, CPAP rapidly improves oxygenation by re-expanding flooded alveoli and increasing functional residual capacity, thereby positioning the lung more favorably on its compliance curve. 25 These effects lead to a reduction in the work of breathing and can improve cardiac performance. 25-28 The latter effect is achieved by raising pericardial pressure and lowering left ventricular transmural pressure (systolic wall stress), and thereby decreasing afterload. 29, 30 This favorable hemodynamic effect is most likely to occur when filling pressure is high and ventricular performance is poor. 30 Crane et al reported that patients presenting with acute cardiogenic pulmonary edema were more likely to survive to hospital discharge if treated with CPAP than with Bilevel-PAP or conventional oxygen therapy. 7 Meta-analyses have shown that NIV, especially CPAP, improves survival rate in patients with cardiogenic pulmonary edema. 9-12, 14 In the present cohort study, NIV was effective in improving vital signs and oxygenation in patients with cardiogenic pulmonary edema of all etiologies, including AMI. NIV resulted in significant improvements in heart rate, blood pressure, respiratory rate, PaO2/FiO2, PaCO2, and pH within 1 h of starting treatment in both the AMI and non-AMI groups. Several studies have found that a patient's response to NIV at 1 h after initiation of treatment is associated with the success rate. 31- 33 The intubation rate in the present study was 11.7%, which is consistent with previous reports. 6,8,34 NIV reduces the risk of endotracheal intubation to nearly half when compared with standard therapy. 10-12 A late requirement for intubation after weaning from NIV was significantly more frequent in the AMI group. In a recent large trial, 22% of patients with Killip class III heart failure on admission developed cardiogenic shock during hospitalization. 35 Wu et al 36 reported that patients presenting with congestive heart failure experience more adverse clinical outcomes, including recurrent AMI, stroke, malignant arrhythmia, cardiac rupture, and unexpected death. All patients except for one in the AMI group underwent percutaneous coronary intervention in the catheterization laboratory and our results show that NIV can be used effectively and safely during catheterization procedures. However, the latest Canadian guide- A high initial systolic blood pressure tended to protect against intubation, which is consistent with previous studies. 7, 16 Hypertension on admission probably indicates acute elevation of filling pressure, often with preserved systolic function. 38 The effects of vasodilators can also be expected to be favorable in these patients. Bilevel-PAP, but not CPAP, has been found to be associated with an increased incidence of AMI, 39 and AMI occurred in 5.2% of the non-AMI group in this study. A randomized trial 33 and recent meta-analyses 11-14 did not find significant differences in the incidence of AMI when comparing CPAP with Bilevel-PAP.
The CCU mortality rate tended to be higher in the AMI group than in the non-AMI group. Our data suggest that the prognosis of AMI patients treated with NIV depends primarily on the severity of the course of AMI and not on the severity of acute respiratory failure. In the AMI group, dopamine was administered significantly more frequently, and intra-aortic balloon pumping was used in 45%, indicating that a large number of high-risk patients were included in the group. The CCU mortality rate of the AMI group tended to be higher in patients with IABP use than in those without IABP use (16.7% vs. 3.4%, P=0.164). Rustherholz et al conducted a non-controlled study of patients treated with NIV (Bilevel-PAP), and reported a poorer response in AMI patients than non-AMI patients, 34 which may have been because of the negative prognosis of AMI itself. Patients presenting with congestive heart failure experience more adverse clinical outcomes, including recurrent AMI, stroke, malignant arrhythmia, cardiac rupture, and unexpected death. 36 
Study Limitations
The results of this study require careful interpretation. First, this was a retrospective, single-center study of a relatively small number of patients. Second, each patient's respiratory management was decided by their physician, introducing a natural bias. However, staff in the CCU are very experienced and welltrained in the use of NIV in patients with acute cardiogenic pulmonary edema. Furthermore, the present study involves the largest population of patients with pulmonary edema secondary to AMI who were treated with NIV that has been reported to date. The results clarify the efficacy of NIV in cardiogenic pulmonary edema of all etiologies, including AMI. Pulmonary edema secondary to AMI appears to be a good indication for NIV, as also indicated by the results of a previous meta-analysis. 14 
Conclusions
NIV can be used successfully in patients with cardiogenic pulmonary edema secondary to AMI, with endotracheal intubation being avoided in 83% of patients in the present study. NIV was effective in improving vital signs and oxygenation, and in lowering the intubation rate, in patients with cardiogenic pulmonary edema of all etiologies, including AMI. The outcome of patients with AMI treated with NIV depends primarily on the severity of the course of AMI and not on the severity of acute respiratory failure.
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